Propanc Biopharma (PPCB) Operating Expenses (2010 - 2025)
Propanc Biopharma (PPCB) posted quarterly Operating Expenses of $3.7 million for Q4 2025, up 1612.77% year-over-year from $213382.0 in Q4 2024, and down 21.8% quarter-over-quarter from $4.7 million in Q3 2025.
Propanc Biopharma (PPCB) Operating Expenses (2010 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Operating Expenses for 16 consecutive years, with $3.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Expenses rose 1612.77% year-over-year to $3.7 million; the TTM figure through Dec 2025 stood at $65.1 million (up 5394.15% YoY), while the FY2025 annual figure was $57.3 million, up 3628.93% from the prior year.
- Operating Expenses retreated to $3.7 million in Q4 2025 per PPCB's latest filing, from $4.7 million in the prior quarter.
- Across five years, Operating Expenses topped out at $53.1 million in Q1 2025 and bottomed at $209602.0 in Q2 2023.
- Historically, Operating Expenses has averaged $3.6 million across 5 years, with a median of $462047.0 in 2021.
- Annual changes were most pronounced in 2023 — Operating Expenses slumped 65.02% — and 2025, when it surged 12523.63%.
- Propanc Biopharma's Operating Expenses stood at $403467.0 in 2021, then surged by 50.69% to $608004.0 in 2022, then retreated by 27.95% to $438064.0 in 2023, then tumbled by 51.29% to $213382.0 in 2024, then surged by 1612.77% to $3.7 million in 2025.
- Business Quant data shows PPCB's Operating Expenses at $3.7 million in Q4 2025, $4.7 million in Q3 2025, and $3.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 3.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.65 Mn |
| Sep 30, 2025 | 4.67 Mn |
| Jun 30, 2025 | 3.65 Mn |
| Mar 31, 2025 | 53.13 Mn |
| Dec 31, 2024 | 213,382.00 |
| Sep 30, 2024 | 290,790.00 |
| Jun 30, 2024 | 259,899.00 |
| Mar 31, 2024 | 420,867.00 |
| Dec 31, 2023 | 438,064.00 |
| Sep 30, 2023 | 417,219.00 |
| Jun 30, 2023 | 209,602.00 |
| Mar 31, 2023 | 386,209.00 |
| Dec 31, 2022 | 608,004.00 |
| Sep 30, 2022 | 572,830.00 |
| Jun 30, 2022 | 599,192.00 |
| Mar 31, 2022 | 502,181.00 |
| Dec 31, 2021 | 403,467.00 |
| Sep 30, 2021 | 486,030.00 |
| Jun 30, 2021 | 726,936.00 |
| Mar 31, 2021 | 427,952.00 |